Notable Labs

Notable Labs Payables Turnover

The Payables Turnover Ratio of Notable Labs (NTBLQ) as of Nov 8, 2026 is 0.11. In the previous year, Payables Turnover Ratio was 0.12 — a change of -11.20% (lower).

Payables Turnover

0.11

YoY

-11.20%

Last updated:

Payables Turnover Ratio of Notable Labs is 2023 0.11 . Payables Turnover Ratio of Notable Labs was 2022 0.12 . It decreases by -11.20% lower compared to the previous year.

The Notable Labs Payables Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Payables Turnover
Date
Payables Turnover
Jan 1, 2017
0.11 USD
Jan 1, 2018
0.22 USD
Jan 1, 2019
0.07 USD
Jan 1, 2020
0.20 USD
Jan 1, 2021
0.09 USD
Jan 1, 2022
0.12 USD
Jan 1, 2023
0.11 USD
The Notable Labs Payables Turnover history
YEARPayables TurnoverYoY
0.11-11.20%
0.12+44.48%
0.09-57.06%
0.20+201.18%
0.07-69.76%
0.22+96.64%
0.11—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Notable Labs Stock analysis

What does Notable Labs do? Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company developing targeted medicines for cancer and immune-inflammatory diseases. The company leverages two platform technologies: Vascular Targeting System (VTS), a gene-based approach targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based method inhibiting monocyte migration. Its product candidates aim to improve patient outcomes by overcoming limitations of current treatments. The firm's pipeline focuses on difficult-to-treat conditions, with VTS and MTT serving as the core technologies for developing therapeutics. VTS targets cancer by focusing on blood vessel formation, while MTT addresses immune-inflammatory diseases through monocyte migration control. These technologies enable the creation of next-generation medicines that address unmet medical needs. Notable Labs Ltd sells its product candidates to pharmaceutical companies and healthcare providers for further development and clinical trials. The primary buyers are biopharmaceutical firms seeking innovative therapies, particularly those targeting cancer and immune-inflammatory conditions. The company's revenue model relies on licensing agreements and partnerships with these industry players to advance its pipeline. Notable Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Notable Labs stock

Payables Turnover Ratio of Notable Labs is 0.11 in 2023.

Payables Turnover Ratio of Notable Labs changed from 0.12 to 0.11, representing a -11.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Payables Turnover Ratio Notable Labs since 2006 – with annual values, charts, and detailed analysis.

Payables turnover measures how quickly a company pays its suppliers. Lower turnover may indicate better payment terms or cash flow management.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Payables Turnover Ratio's Notable Labs with sector peers and the industry average to assess whether it is attractive.

To evaluate Payables Turnover Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Payables Turnover Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Notable Labs

All Key Metrics — Notable Labs